Our website is now live and our first tweet is out. Check us out at togethertrial.com and follow us for upcoming information on the TOGETHER Trial #covidtrials #covid19

"The need for treatments in early disease is paramount. Evidence is quickly emerging that suggests a number of drugs may have a promising effect on reducing COVID-19 disease severity in patients with mild to moderate disease” - Dr. Edward Mills, principal investigator

“Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.” - NIH recommendation Feb 11th 2021 Alright. togethertrial.com

The previous iteration of the TOGETHER Trial evaluating HCQ and LPV/r was stopped by our DSMB for futility - (publication soon). The story of HCQ was one of unnecessary politicisation. Here is a narrative commentary by our team on the Rise and Fall of HCQ. pubmed.ncbi.nlm.nih.gov/33236703/

A well-researched article summarizing the findings of trials, including Together Trial, evaluating the effectiveness of repurposed therapies for outpatient treatment fo COVID-19 by Esther Wei-Yun Landhuis

The updated TOGETHER Trial schema is now posted to our website. togethertrial.com

Our first evaluation of HCQ and LPV/r is also published now in JAMA Open Network. You can access it here. jamanetwork.com/journals/jaman…

Correction: The switch to three doses of Ivermectin in the TOGETHER Trial occurred before the most recent interim analysis. The trial schema has been updated on the website.

Inexpensive anti-depressant could be best COVID treatment yet, Canadian-led trial finds nationalpost.com/health/inexpen…

In 20 Jan 2021 Together Trial enrolled its first patient. Exactly one year later nobody could predict these waves and variants of concern that are still overcrowding public health worldwide. Still so much to learn! #COVID19 #Omicron #research NIH APHA GloboNews

TOGETHER Study finds ivermectin no more beneficial than placebo in reducing hospitalisations or ER observations >6 hours in 12 sites, double-blind, platform RCT in Brazil nejm.org/doi/full/10.10…